Canaccord Genuity Maintains Buy on Stoke Therapeutics, Raises Price Target to $60

Canaccord Genuity analyst Sumant Kulkarni has maintained a Buy rating on Stoke Therapeutics (NASDAQ: STOK) and raised the price target from $36 to $60.